Health care giant Johnson & Johnson announced Thursday that it has appointed Ryan Koors as vice president, Investor Relations, effective May 7.
Koors, a veteran finance executive with over two decades of experience at the company, will report directly to Johnson & Johnson’s executive vice president and chief financial officer, Joseph Wolk. He succeeds Darren Snellgrove, who is departing the New Brunswick-based firm to take on the role of chief financial officer at Halozyme.
Koors joined Johnson & Johnson in 2002 and has climbed the ranks through several high-stakes financial leadership roles. His background spans the company’s most critical sectors, including Innovative Medicine, MedTech, and Global Supply Chain.
Notable previous roles include:
- CFO & VP of Finance: Innovative Medicine Global Research & Development.
- VP of Finance: MedTech Surgery.
- VP of Finance: Johnson & Johnson MedTech, Supply Chain.
“Ryan’s appointment underscores the deep bench of financial talent within Johnson & Johnson,” said CFO Joseph J. Wolk. “With his deep knowledge of our business and proven financial expertise, Ryan is exceptionally well-positioned to lead our Investor Relations function and will be a great resource to the investment community.”
The appointment comes at a pivotal time for Johnson & Johnson as it continues to execute a long-term strategy focused on “sustained and accelerating growth” following its recent corporate restructuring. Koors will be the primary point of contact for the global investment community, tasked with communicating the company’s value proposition across its pharmaceutical and medical technology portfolios.
Koors holds a bachelor’s degree in finance from Wright State University and an MBA from Xavier University.
The move also marks the end of Darren Snellgrove’s tenure at J&J. Wolk expressed his gratitude for Snellgrove’s contributions, wishing him success in his new executive role at Halozyme.
As the “health of the business” remains a top priority for Wall Street, Koors’ deep institutional knowledge is expected to provide a seamless transition for analysts and shareholders alike.
